Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Key Points

• The Goldman Sachs Group raised its price target on Agios from $28 to $32 while keeping a "neutral" rating, implying roughly a 6.9% downside versus the current price; the Street consensus is a "Hold" with an average price target of $41.44.
• Agios plans to pursue U.S. accelerated approval for mitapivat in sickle cell disease after a pre‑sNDA FDA meeting, a development analysts say provides a clearer regulatory pathway and sparked an intraday rally on hopes of earlier label expansion and revenue upside.
• Two law firms have opened investigations related to Agios' RISE UP topline results, creating a potential litigation and disclosure overhang that could offset positive regulatory and commercial news.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) had its target price lifted by analysts at The Goldman Sachs Group from $28.00 to $32.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's price objective would suggest a potential downside of 6.88% from the stock's current price.

AGIO has been the subject of several other reports. Leerink Partners lifted their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, December 26th. Bank of America boosted their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, December 24th. JPMorgan Chase & Co. increased their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 6th. Citigroup raised their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Agios Pharmaceuticals in a research note on Friday. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $41.44.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded up $0.53 during trading hours on Wednesday, reaching $34.36. 765,496 shares of the company's stock were exchanged, compared to its average volume of 910,291. The company's 50-day moving average is $28.47 and its two-hundred day moving average is $32.17. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -4.84 and a beta of 0.89.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Krishnan Viswanadhan sold 2,959 shares of the business's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the transaction, the insider owned 5,141 shares of the company's stock, valued at approximately $142,919.80. The trade was a 36.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tsveta Milanova sold 2,872 shares of the business's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $27.02, for a total value of $77,601.44. Following the transaction, the insider directly owned 34,793 shares of the company's stock, valued at $940,106.86. This trade represents a 7.63% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.93% of the stock is owned by corporate insiders.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently bought and sold shares of AGIO. Wellington Management Group LLP lifted its holdings in shares of Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $35,478,000. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock valued at $84,604,000 after purchasing an additional 845,433 shares during the last quarter. TCG Crossover Management LLC increased its position in Agios Pharmaceuticals by 105.2% during the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company's stock worth $57,402,000 after purchasing an additional 733,038 shares in the last quarter. Finally, Capital International Investors acquired a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $19,159,000.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease after a pre‑sNDA meeting with the FDA; the company plans to submit the sNDA in coming months and has already proposed a confirmatory trial. Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease
• Positive Sentiment: Analysts and media reported regulatory feedback as a clear pathway toward accelerated approval, which triggered a sharp intraday rally on hopes of earlier label expansion and revenue upside. AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
• Positive Sentiment: Commercial update: early uptake of Agios’ Aqvesme in thalassemia shows promising clinician interest (up to ~1/3 of patients seen as candidates), supporting longer‑term revenue diversification. PK Activation Gains Momentum in Thalassemia
• Neutral Sentiment: Coverage notes the stock’s recent above‑average volume and earnings‑estimate revision trend, implying analysts are re‑rating the story but cautioning on sustainability. Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
• Neutral Sentiment: An insider sale of roughly $82k in AGIO stock was reported; the firm notes context matters (small dollar size vs. company market cap). Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
• Negative Sentiment: Levi & Korsinsky launched an investigation into possible securities‑law violations related to Agios’ RISE UP topline results, creating legal and disclosure overhang. Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
• Negative Sentiment: The Gross Law Firm also opened an investigation into potential securities fraud claims tied to the same disclosures, adding to litigation risk. AGIO ALERT- The Gross Law Firm Has Commenced an Investigation
• Negative Sentiment: Technically, AGIO recently slipped below its 200‑day moving average, which can attract short‑term selling pressure from technical traders. Agios Pharmaceuticals NASDAQ: AGIO Stock Passes Below 200 Day Moving Average

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.